Silver Spring, MD, United States
Silver Spring, MD, United States

Time filter

Source Type

News Article | December 26, 2016
Site: www.eurekalert.org

Tens of millions of ash trees across Europe are dying from the Hymenoscyphus fraxinea fungus - the most visible signs that a tree is infected with ash dieback fungus are cankers on the bark and dying leaves. Project leader Dr Richard Buggs from QMUL's School of Biological and Chemical Sciences said: "This ash tree genome sequence lays the foundations for accelerated breeding of ash trees with resistance to ash dieback." A small percentage of ash trees in Denmark show some resistance to the fungus and the reference genome is the first step towards identifying the genes that confer this resistance. The ash tree genome also contains some surprises. Up to quarter of its genes are unique to ash. Known as orphan genes, they were not found in ten other plants whose genomes have been sequenced. Dr Buggs added: "Orphan genes present a fascinating evolutionary conundrum as we have no idea how they evolved." This research is published today in the journal Nature. It involved a collaboration between scientists at: QMUL, the Earlham Institute, Royal Botanic Gardens Kew, University of York, University of Exeter, University of Warwick, Earth Trust, University of Oxford, Forest Research, Teagasc, John Innes Centre, and National Institute of Agricultural Botany. The reference genome from QMUL was used by scientists at York University who discovered genes that are associated with greater resistance to ash dieback. They have used these to predict the occurrence of more resistant trees in parts of the UK not yet affected by the disease, which is spreading rapidly. The genome sequence will also help efforts to combat the beetle Emerald Ash Borer, which has killed hundreds of millions of ash trees in North America. Ash trees have a huge significance in culture and society - they are one of the most common trees in Britain and over 1,000 species, from wildflowers to butterflies, rely on its ecosystem for shelter or sustenance. Ash timber has been used for years for making tools and sport handles, for example hammers and hockey sticks, and is used often for furniture. The work was funded by NERC, BBSRC, Defra, ESRC, the Forestry Commission, the Scottish Government, Marie Sklodowska-Curie Actions, Teagasc - the Agriculture and Food Development Authority. 'Genome sequence and genetic diversity of European ash trees' by E. Sollars et al is published in the journal Nature on Monday 26 December 2016. For further details, images or to arrange interviews with the author please contact the press office. Could disease 'tolerance' genes give new life to UK ash trees? Researchers at the University of York have identified genetic markers for disease tolerance that suggest UK ash trees may have a fighting chance against a fungal infection, which has the potential to wipe out 90% of the European ash tree population. The disease, called ash dieback, was first identified in Poland, where it devastated the native ash tree population. It rapidly spread across northern Europe, and was discovered in the UK in 2012. Results from the latest study, a collaboration between the University of York and Queen Mary University of London, could contribute to breeding new varieties of ash that are tolerant to the disease. The disease is aggressive, spreads quickly through the population, and has no cure, other than individual natural tolerance to the infection. It is spread on the wind or via the transfer of infected saplings between areas. Symptoms include loss of leaves and lesions, which are a useful way to diagnose fungal ash dieback, as they leave a characteristic diamond shape scar on the bark. Professor Ian Bancroft, plant biologist at the University of York, said: "This disease has spread across Europe in less than 10 years so there is some urgency to understand how we can better support breeding programmes for the species. "Ash trees can be found in home gardens, parks, and roadsides and are an important woodland species that support a number of insects and fungi. It is not known exactly how the loss of this tree species will impact the eco-system, but from past examples, we know that the extinction of any species can fundamentally alter the environment." The York team had previously tested a genetic screening process on Danish trees. Using this data alongside information from the ash tree genome, which was sequenced by researchers at Queen Mary University of London (QMUL), they were able to improve the genetic markers for disease tolerance, and use them to predict the tolerance of a sample of trees from across the UK. Early indications suggest that the proportion of UK trees with tolerance to ash dieback is greater than that of the Danish and Polish trees, but it is still unknown whether the UK trees have previously been infected with the disease and built tolerance or whether their genetic tolerance is yet to be tested. Dr Andrea Harper, plant biologist at the University of York, said: "Working with DEFRA, the next stage of this work will be to establish a UK panel suitable for identifying additional, UK-specific, markers for tolerance. This will improve our predictions on individual trees, and provide more information about why some trees are tolerant to the disease. It will also support breeding programmes to develop tolerant varieties of ash." The research, funded by BBSRC and Defra, is published in the journal, Nature. Supportive press release from University of Exeter and University of Warwick: Ash trees which can resist the killer dieback fungus may be more vulnerable to attacks by insects, according to new research. Scientists from the universities of Exeter and Warwick examined trees which are resistant to ash dieback and - unexpectedly - found they had very low levels of chemicals which defend against insects. With efforts under way to protect ash trees from dieback, the scientists warn that selecting trees for fungal resistance could put them at risk from insects. Aside from ash dieback, the other major threat to European ash trees is the Emerald Ash Borer beetle, which has already devastated vast tracts of ash in the USA and is currently spreading westwards across Europe. "Our research highlights the danger of selecting trees for resilience to ash dieback at the expense of resistance to insects that threaten this iconic UK tree species," said joint lead author Dr Christine Sambles, of the University of Exeter. "Ash dieback, which is caused by a fungus called Hymenoscyphus fraxineus, can kill young trees in a season, while older trees tend to decline and die over several years." The research, published in the journal Nature, is part of a study involving several universities and Government institutes which looked at the DNA of ash trees in the hope of identifying ash dieback resistance. Instead of focussing on DNA, the Exeter and Warwick scientists looked at differences in chemical composition between tolerant and susceptible ash trees. "Plants use a vast range of chemicals to defend against fungal attack, and the primary objective was to identify differences which could be used to screen young ash trees and choose the best ones for replanting," said co-author Professor Murray Grant, Elizabeth Creak Chair in Food Security at the University of Warwick. "Our findings underline the need for further research to ensure that we select ash trees resilient to present and future threats." Co-author Dr David Studholme, of the University of Exeter, added: "These findings highlight Exeter's world-class expertise in high-impact, integrative plant science underpinned by key research infrastructure, such as the Mass Spectrometry facility." Researchers have identified genetic markers for disease tolerance that suggest UK ash trees may have a fighting chance against a fungal infection that has the potential to wipe out 90% of the European ash tree population. The disease, called ash dieback, was first identified in Poland, where it devastated the native ash tree population. It rapidly spread across northern Europe, and was discovered in the UK in 2012. Results from the latest study published in Nature, a UK collaboration between Queen Mary University of London (QMUL), University of York, Earlham Institute (EI), John Innes Centre (JIC), NIAB and the University of Copenhagen, could contribute to breeding new varieties of ash that are tolerant to the disease. Much like Dutch elm disease, ash dieback is aggressive, spreads quickly through the ash tree population, and has no cure, other than individual natural tolerance to the infection. It is spread on the wind or via the transfer of infected saplings between areas. Symptoms include loss of leaves and lesions, which are a useful way to diagnose fungal ash dieback, as they leave a characteristic diamond-shaped scar on the bark. The York team had previously tested a genetic screening process on Danish trees identified by collaborators at the University of Copenhagen as having a range of different levels of disease susceptibility. Using this data alongside information from the ash tree genome, which was sequenced by researchers at QMUL by utilising EI's reference gene models, they were able to improve the genetic markers for disease tolerance, and use them to predict the tolerance of a sample of trees from across the UK. Leading to these research findings, EI (previously 'The Genome Analysis Centre') generated the transcriptome and re-sequencing (together with the Institute's previous analysis of the resistant 'Tree 35' from Denmark released in 2013) data to conduct the bioinformatics analysis of the UK ash tree, in alignment with the Nornex Consortium to combat Ash Dieback, funded by DEFRA and BBSRC. The analysis was carried out on a subset of the tree's genetic regions, with high coverage across the samples. This increased the number of potential markers that could be used to sustain ash tree diversity for breeding programmes. EI also sequenced 37 trees originating from across Europe to investigate genomic diversity in ash. The data were analysed by researchers at QMU, JIC and NIAB finding evidence for apparent long-term decline in effective population size. The EI team generated the most comprehensive annotation of ash genes to date, and this will aid researchers in identifying genetic variants linked to specific traits associated with the killer tree disease. This will help seek out the suspected tolerant genes and support future breeding programmes of ash trees with low susceptibility to the disease. Dr David Swarbreck, Regulatory Genomics Group Leader at EI, said: "Having a more comprehensive annotation of ash genes has improved the identification of markers for ash dieback and will aid future functional studies into this prevalent disease." Professor Mario Caccamo, previously at EI, now Head of Crop Bioinformatics at NIAB, added: "This effort is a great example of team-work across several leading UK research organisations responding to the devastating threat of ash dieback. The identification of markers for tolerance will be a very important tool in the toolbox that complements other ongoing efforts to manage the threat of this disease. We have also generated important genomic resources that will support other studies and offer the foundations for more research into tackling the epidemic." Professor Allan Downie, Emeritus Fellow at JIC and coordinator of the NORNEX programme, commented: "This work represents significant new progress in our understanding of ash dieback disease and the patterns of inheritance of tolerance to this disease. Our success has been built on excellent national and international collaborations. These have brought the strengths of genomics and transcriptomics research in the UK together with the excellent analyses of disease susceptibility done in Denmark, to enhance our research into UK ash trees. This progress has been breath-taking in its speed and as a research coordinator based at JIC; I have been delighted by the spirit of collaboration and determination brought to this project by my Danish and UK collaborators. Early indications suggest that the proportion of UK trees with tolerance to ash dieback is greater than that of the Danish and Polish trees, but it is still unknown whether the UK trees have previously been infected with the disease and built tolerance or whether this is due to their genetic tolerance, is yet to be tested. The study, "Genome sequence and genetic diversity of European ash trees" is published in the journal, Nature. A team of scientists have successfully decoded the genetic sequence of the ash tree, to help the fight against the fungal disease, ash dieback. In a paper published by the journal Nature today, a team of researchers led by Richard Buggs, who heads up plant health research at the Royal Botanic Gardens, Kew, assembled a reference genome and analysed the diversity of ash trees throughout Europe. Their collaborators have used this resource to identify genes that may be associated with low susceptibility to ash dieback. They used these to predict the effect that ash dieback will have on ash trees all over Britain. The genome sequence will also help efforts to combat the beetle Emerald Ash Borer, which has already killed hundreds of millions of ash trees in North America. Project Leader Dr Richard Buggs, Senior Research Leader (Plant Health) at RBG Kew who conducted the work at Queen Mary University of London's (QMUL) School of Biological and Chemical Sciences said: "This is the first time a plant genome has been rapidly sequenced in response to an emerging disease threat, leading to an assessment of the susceptibility of as yet uninfected populations. Kew is continuing to work with the latest genomic technologies to increase the armoury of methods that can be deployed against plant pests and pathogens." There are 520 specimens of the Ash tree at Kew and its Sussex site, Wakehurst (227 of these are at Kew). At Kew's Millennium Seed bank scientists are also involved in gathering seed of different ash populations around Britain to help inform broader efforts to control disease spread and drive plant health policy.


Zhang L.,Genomics Group | Yin S.,Genomics Group | Miclaus K.,SAS Institute | Chierici M.,Fondazione Bruno Kessler | And 6 more authors.
Pharmacogenomics Journal | Year: 2010

The robustness of genome-wide association study (GWAS) results depends on the genotyping algorithms used to establish the association. This paper initiated the assessment of the impact of the Corrected Robust Linear Model with Maximum Likelihood Classification (CRLMM) genotyping quality on identifying real significant genes in a GWAS with large sample sizes. With microarray image data from the Wellcome Trust Case-Control Consortium (WTCCC), 1991 individuals with coronary artery disease (CAD) and 1500 controls, genetic associations were evaluated under various batch sizes and compositions. Experimental designs included different batch sizes of 250, 350, 500, 2000 samples with different distributions of cases and controls in each batch with either randomized or simply combined (4:3 case-control ratios) or separate case-control samples as well as whole 3491 samples. The separate composition could create 2-3% discordance in the single nucleotide polymorphism (SNP) results for quality control/statistical analysis and might contribute to the lack of reproducibility between GWAS. CRLMM shows high genotyping accuracy and stability to batch effects. According to the genotypic and allelic tests (P5.0 × 10 -7), nine significant signals on chromosome 9 were found consistently in all batch sizes with combined design. Our findings are critical to optimize the reproducibility of GWAS and confirm the genetic role in the pathophysiology of CAD. © 2010 Macmillan Publishers Limited. All rights reserved.


Hong H.,National Center for Toxicological Research (NCTR) | Goodsaid F.,Genomics Group | Shi L.,National Center for Toxicological Research (NCTR) | Tong W.,National Center for Toxicological Research (NCTR)
Biomarkers in Medicine | Year: 2010

Molecular biomarkers are used for various purposes, including disease diagnosis and prognosis, prediction and assessment of treatment response, and safety assessment. There has been a significant increase in the number of US FDA-approved drug labels containing information on molecular biomarkers over the last decade. Almost every pharmaceutical company has been developing molecular biomarker programs, either alone, through partnerships or other ventures. More molecular biomarkers are expected to be identified and validated in drug development, and used to support approval of drug products. This article summarizes the current status of molecular biomarkers used for FDA-approved drug products, and discusses the challenges and future perspectives for the identification and qualification of molecular biomarkers. Specific FDA programs and research projects related to molecular biomarkers are also discussed for supporting regulatory review in the future. © 2010 Future Medicine Ltd.


Tesch G.,Monash Medical Center | Amur S.,Genomics Group | Schousboe J.T.,Minneapolis | Schousboe J.T.,University of Minnesota | And 3 more authors.
AAPS Journal | Year: 2010

Biomarkers are important tools for identifying and stratifying diseases, predicting their progression and determining the effectiveness, safety, and doses of therapeutic interventions. This is important for common chronic diseases such as diabetic nephropathy, osteoporosis, and rheumatoid arthritis which affect large numbers of patients worldwide. This article summarizes the current knowledge of established and novel biomarkers for each of these diseases as presented at the 2008 AAPS/ACCP joint symposium "Success Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications," in Atlanta, Georgia. The advantages and disadvantages of various proteomic, metabolomic, genomic, and imaging biomarkers are discussed in relation to disease diagnosis and stratification, prognosis, drug development, and potential clinical applications. The use of biomarkers as a means to determine therapeutic interventions is also considered. In addition, we show that biomarkers may be useful for adapting therapies for individual needs by allowing the selection of patients who are most likely to respond or react adversely to a particular treatment. They may also be used to determine whether the development of a novel therapy is worth pursuing by informing crucial go/no go decisions around safety and efficacy. Indeed, regulatory bodies now suggest that effective integration of biomarkers into clinical drug development programs is likely to promote the development of novel therapeutics and more personalized medicine. © 2010 American Association of Pharmaceutical Scientists.


Pacanowski M.A.,Genomics Group | Zineh I.,Genomics Group
Drug Discovery Today: Therapeutic Strategies | Year: 2012

Drug safety is a priority for drug developers and regulatory agencies. Pharmacogenomics is a powerful tool that can be used to manage clinical risks as well as resolve the mechanistic basis of adverse drug events. Advances in the science of drug safety, increased commitment to pharmacogenomics by drug companies, and enhanced regulatory review infrastructure at the U.S. FDA have helped to advance the application of safety pharmacogenomics in drug development and public health decision-making. This review highlights some successes in discovery and translation of pharmacogenomic biomarkers for adverse drug events and outlines future strategies to optimize the development and clinical application of pharmacogenomic information. © 2012 Elsevier Ltd. All rights reserved.


Zineh I.,Genomics Group | Mummaneni P.,Genomics Group | Lyndly J.,Center for Drug Evaluation and Research | Amur S.,Genomics Group | And 4 more authors.
Pharmacogenomics | Year: 2011

Use of pharmacogenetics to inform treatment decisions remains a priority for clinicians, patients and public health agencies. We previously developed a framework for systematically assessing whether pharmacogenetic test information would likely bring value to clinical decision-making and enjoy practical uptake. We applied this tool to allopurinol to determine potential usefulness of HLA genetic information in assessing risk for allopurinol-induced severe cutaneous adverse reactions. We quantified allopurinol use data and the magnitude of adverse event signals using US FDA databases, reviewed reported cases of allopurinol-associated severe cutaneous adverse reactions to assess whether clinical subtypes of patients could be identified, performed pooled analyses of associations between HLA variation and allopurinol-induced severe cutaneous adverse reactions and described considerations in clinical implementation of allopurinol pharmacogenetics. © 2011 Future Medicine Ltd.


News Article | February 15, 2017
Site: www.businesswire.com

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.07 billion, up 3.8 percent year over year (up 4.8 percent on a core basis(2)) for the first fiscal quarter ended Jan. 31, 2017. First-quarter GAAP net income was $168 million, or $0.52 per share. Last year’s first-quarter GAAP net income was $121 million, or $0.36 per share. During the first quarter, Agilent had intangible amortization of $31 million, acquisition and integration costs of $16 million, transformation costs of $2 million and $2 million of other costs. Excluding these items, a pension settlement gain of $32 million and a tax benefit of $15 million, Agilent reported first-quarter non-GAAP net income of $172 million, or $0.53 per share(1). “ The Agilent team started 2017 with another strong quarter, despite currency headwinds,” said Mike McMullen, Agilent president and CEO. “ Our first-quarter revenue and non-GAAP earnings per share(1) exceeded the high end of November’s guidance. “ Our strong revenue results were driven by a return to growth in our Chemical & Energy business and higher-than-expected China growth. Overall, we are confident in the company’s prospects, and we are raising our full-year core revenue growth expectations,” McMullen added. First-quarter revenue of $540 million from Agilent’s Life Sciences and Applied Markets Group (LSAG) grew 3 percent year over year (up 4 percent on a core basis(2)), with strength in pharma, food, chemical and energy. LSAG’s Q1 operating margin for the quarter was 23.4 percent. First-quarter revenue of $363 million from the Agilent CrossLab Group (ACG) grew 6 percent year over year (up 7 percent on a core basis(2)). Both services and consumables experienced healthy growth across all geographies. ACG’s operating margin for the quarter was 20.3 percent. First-quarter revenue of $164 million from Agilent’s Diagnostics and Genomics Group (DGG) grew 4 percent year over year (also up 4 percent on a core basis(2)), led by strength in Dako-branded products and nucleic acid solutions. DGG’s operating margin for the quarter was 14.3 percent. Agilent expects second-quarter 2017 revenue in the range of $1.04 billion to $1.06 billion. Second-quarter non-GAAP earnings are expected to be in the range of $0.47 to $0.49 per share(3). For fiscal year 2017, Agilent expects revenue of $4.33 billion to $4.35 billion and non-GAAP earnings of $2.10 to $2.16 per share(3). The guidance is based on Jan. 31, 2017 currency exchange rates. Agilent Technologies, Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenue of $4.20 billion in fiscal 2016. The company employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com. Agilent’s management will present more details about its first-quarter FY2017 financial results on a conference call with investors today at 1:30 p.m. PT. This event will be webcast live in listen-only mode. Listeners may log on at www.investor.agilent.com and select “ Q1 2017 Agilent Technologies Inc. Earnings Conference Call” in the “News & Events Calendar of Events” section. The webcast will remain available on the company’s website for 90 days. Additional information regarding financial results can be found at www.investor.agilent.com by selecting “Financial Results” in the “Financial Information” section. A telephone replay of the conference call will be available at approximately 4:30 p.m. PST today through Feb. 21 by dialing +1 855-859-2056 (or +1 404-537-3406 from outside the United States) and entering pass code 56828410. This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s future revenue, earnings and profitability; planned new products; market trends; the future demand for the company’s products and services; customer expectations; and revenue and non-GAAP earnings guidance for the second quarter and full fiscal year 2017. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including our annual report on form 10-K for the year ended Oct. 31, 2016. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement. (1) Non-GAAP net income and non-GAAP earnings per share primarily excludes the impacts of acquisition and integration costs, transformation initiatives, business exit and divestiture costs, non-cash intangibles amortization, and pension settlement and curtailment gains. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or is not expected to occur again with any regularity or predictability. A reconciliation between non-GAAP net income and GAAP net income is set forth on page 5 of the attached tables along with additional information regarding the use of this non-GAAP measure. (2) Core revenue growth excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. A reconciliation between Q1 FY17 GAAP revenue and core revenue is set forth on page 7 of the attached tables along with additional information regarding the use of this non-GAAP measure. Core revenue growth as projected for full fiscal year 2017 excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Most of these exclude amounts that pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided. (3) Non-GAAP earnings per share as projected for Q2 FY17 and full fiscal year 2017 excludes primarily the future impact of acquisition and integration costs, pension settlement gain, and non-cash intangibles amortization. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or is not expected to occur again with any regularity or predictability. Most of these excluded amounts that pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided. Future amortization of intangibles is expected to be approximately $32 million per quarter. NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news.


News Article | April 28, 2016
Site: www.biosciencetechnology.com

An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies -- according to a new study led by The Genome Analysis Centre (TGAC). New research published today in PLOS ONE reveals an improved annotation of microRNAs in the dog genome to further understand its biological role. Providing a platform for future studies into biomedicine, evolution and the domestication of important animals including dogs, cows, horses and pigs. MicroRNAs (miRNAs) are small non-coding RNA molecules that play a crucial role in regulating gene expression in animals and plants. Using the latest dog genome assembly and small RNA sequences of nine different dog tissues including skin, blood, ovaries and testes, scientists from TGAC have identified 91 novel miRNAs. This discovery provides a significant opportunity not only to enhance our understanding of how miRNAs regulate a variety of biological processes in an important model species for studying human diseases, but can lead to further, similar research into the role that miRNAs play in animal domestication. Lead researcher, Dr. Luca Penso Dolfin from TGAC's Vertebrate & Health Genomics Group, said: "As miRNAs are so important in orchestrating a variety of cellular processes, the discovery of these 91 novel miRNAs provides a vital starting point to explore their potentially major effects on gene regulation." Overall, 811 miRNAs were analyzed by Dr. Penso-Dolfin: 91 novel microRNA sequences and 720 conserved (that is, common to other organisms). Among these conserved loci, 207 had not previously been identified as canine microRNAs. Dr. Penso-Dolfin, added: "Our results represent a clear improvement in our knowledge of the dog genome, paving the way for further research on the evolution of gene regulation, and the contribution of microRNAs to pathological conditions. We are now looking at additional data for dog and a variety of farm animals, combining microRNA discovery to the investigation of their possible role in domestication." The domestic dog, Canis familiaris, is the result of wolf (Canis lupus) domestication, which started around 10,000 years ago. Since then, hundreds of dog breeds have been artificially selected, leading to very high levels of morphological and behavioural variation. Having shared the environment with humans ever since its appearance, the dog has been exposed to similar pathogens, and therefore represents an important model system for the study of human diseases. The publication of the latest Canine genome build and annotation, CanFam3.1 provides an opportunity to enhance our understanding of gene regulation across tissues in the dog model system.


News Article | February 21, 2017
Site: www.accesswire.com

LONDON, UK / ACCESSWIRE / February 21, 2017 / Active Wall St. announces its post-earnings coverage on Agilent Technologies, Inc. (NYSE: A). The Company announced its first quarter fiscal 2017 financial results on February 14, 2017. The scientific instrument maker reported eighth consecutive quarter of improving profitability and also raised its core revenue guidance for the year. Register with us now for your free membership at: One of Agilent Technologies' competitors within the Medical Laboratories & Research space, Quintiles IMS Holdings, Inc. (NYSE: Q), reported its Q4 and full-year 2016 financial results and issued its 2017 guidance on Tuesday, February 14, 2017. AWS will be initiating a research report on Quintiles IMS Holdings in the coming days. Today, AWS is promoting its earnings coverage on A; touching on Q. Get our free coverage by signing up to: For the period ended January 31, 2017, Agilent reported revenue of $1.07 billion, up 3.8% or 4.8% on core basis compared to revenue of $1.03 billion in Q1 FY16. The Company's revenue numbers surpassed analysts' consensus of $1.04 billion. For Q1 FY17, Agilent reported GAAP net income of $168 million, or $0.52 per share, compared to GAAP net income of $121 million, or $0.36 per share, for Q1 FY16. During the reported quarter, Agilent had intangible amortization of $31 million, acquisition and integration costs of $16 million, transformation costs of $2 million, and $2 million of other costs. Excluding these items, a pension settlement gain of $32 million and a tax benefit of $15 million, Agilent reported Q1 FY17 non-GAAP net income of $172 million, or $0.53 per share, exceeding Wall Street's expectations for earnings of $0.49 per share. Mike McMullen, Agilent's President and CEO stated in regards to the Company's results: "Our strong revenue results were driven by a return to growth in our Chemical & Energy business and higher-than-expected China growth. Overall, we are confident in the Company's prospects, and we are raising our full-year core revenue growth expectations." For Q1 FY17, Agilent reported adjusted operating margin of 21.2%, up 100 basis points from Q1 FY16, and operating cash flow of $116 million, $5 million higher than Q1 of last year. During Q1 FY17, Agilent paid $42 million in dividends and repurchased 2.5 million shares for $111 million in the reported quarter. The Company closed on $70 million Multiplicom acquisition in January 2017. For Q1 FY17, the Company's revenue of $540 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 3% on y-o-y basis, or 4% on a core basis, with strength in Pharma, food, chemical, and energy. LSAG's operating margin for the reported quarter was 23.4%. The Company's Agilent CrossLab Group (ACG) revenue grew 6% y-o-y, or 7% on a core basis, to $363 million. Both services and consumables experienced healthy growth across all geographies. ACG's operating margin for the reported quarter was 20.3%. During Q1 FY17, Agilent's Diagnostics and Genomics Group (DGG) generated revenue of $164 million, up 4% on y-o-y and core basis, led by strength in Dako-branded products and nucleic acid solutions. The segment's operating margin totaled 14.3% for the reported quarter. On a geographical basis, Agilent reported delivering low double digit growth in Q1FY17 in China, above the Company's expectations. The Americas reported growth in mid-single digits, with strength in the United States. Europe and Japan remained flat. For FY17, Agilent expects revenue of $4.33 billion to $4.35 billion and non-GAAP earnings of $2.10 to $2.16 per share. The Company is raising the core revenue growth guidance of 4.0% to 4.5% provided in November by 25 basis points, or $11 million. The new core revenue growth guidance is therefore 4.25% to 4.75%. However, Agilent noted that the strengthening of the US dollar since its November guidance is expected to have a negative impact of about $36 million on full-year reported revenues. The Company's FY17 guidance of $825 million operating cash flow, $200 million CapEx, and buyback of $430 million for the year remained unchanged. For Q2 FY17, Agilent expects revenue in the range of $1.04 billion to $1.06 billion, where the midpoint corresponds to a core revenue growth of 3.5%. The Company's non-GAAP earnings are expected to be in the range of $0.47 to $0.49 per share for Q2 FY17, a 9% y-o-y increase at midpoint. At the closing bell, on Friday, February 17, 2017, Agilent Technologies' stock climbed 1.55%, ending the trading session at $51.63. A total volume of 2.20 million shares were traded at the end of the day, which was higher than the 3-month average volume of 2.05 million shares. In the last three months and previous twelve months, shares of the Company have advanced 12.13% and 39.41%, respectively. Moreover, the stock surged 13.32% since the start of the year. The Company's shares are trading at a PE ratio of 33.22 and have a dividend yield of 1.03%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | February 21, 2017
Site: marketersmedia.com

LONDON, UK / ACCESSWIRE / February 21, 2017 / Active Wall St. announces its post-earnings coverage on Agilent Technologies, Inc. (NYSE: A). The Company announced its first quarter fiscal 2017 financial results on February 14, 2017. The scientific instrument maker reported eighth consecutive quarter of improving profitability and also raised its core revenue guidance for the year. Register with us now for your free membership at: One of Agilent Technologies' competitors within the Medical Laboratories & Research space, Quintiles IMS Holdings, Inc. (NYSE: Q), reported its Q4 and full-year 2016 financial results and issued its 2017 guidance on Tuesday, February 14, 2017. AWS will be initiating a research report on Quintiles IMS Holdings in the coming days. Today, AWS is promoting its earnings coverage on A; touching on Q. Get our free coverage by signing up to: For the period ended January 31, 2017, Agilent reported revenue of $1.07 billion, up 3.8% or 4.8% on core basis compared to revenue of $1.03 billion in Q1 FY16. The Company's revenue numbers surpassed analysts' consensus of $1.04 billion. For Q1 FY17, Agilent reported GAAP net income of $168 million, or $0.52 per share, compared to GAAP net income of $121 million, or $0.36 per share, for Q1 FY16. During the reported quarter, Agilent had intangible amortization of $31 million, acquisition and integration costs of $16 million, transformation costs of $2 million, and $2 million of other costs. Excluding these items, a pension settlement gain of $32 million and a tax benefit of $15 million, Agilent reported Q1 FY17 non-GAAP net income of $172 million, or $0.53 per share, exceeding Wall Street's expectations for earnings of $0.49 per share. Mike McMullen, Agilent's President and CEO stated in regards to the Company's results: "Our strong revenue results were driven by a return to growth in our Chemical & Energy business and higher-than-expected China growth. Overall, we are confident in the Company's prospects, and we are raising our full-year core revenue growth expectations." For Q1 FY17, Agilent reported adjusted operating margin of 21.2%, up 100 basis points from Q1 FY16, and operating cash flow of $116 million, $5 million higher than Q1 of last year. During Q1 FY17, Agilent paid $42 million in dividends and repurchased 2.5 million shares for $111 million in the reported quarter. The Company closed on $70 million Multiplicom acquisition in January 2017. For Q1 FY17, the Company's revenue of $540 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 3% on y-o-y basis, or 4% on a core basis, with strength in Pharma, food, chemical, and energy. LSAG's operating margin for the reported quarter was 23.4%. The Company's Agilent CrossLab Group (ACG) revenue grew 6% y-o-y, or 7% on a core basis, to $363 million. Both services and consumables experienced healthy growth across all geographies. ACG's operating margin for the reported quarter was 20.3%. During Q1 FY17, Agilent's Diagnostics and Genomics Group (DGG) generated revenue of $164 million, up 4% on y-o-y and core basis, led by strength in Dako-branded products and nucleic acid solutions. The segment's operating margin totaled 14.3% for the reported quarter. On a geographical basis, Agilent reported delivering low double digit growth in Q1FY17 in China, above the Company's expectations. The Americas reported growth in mid-single digits, with strength in the United States. Europe and Japan remained flat. For FY17, Agilent expects revenue of $4.33 billion to $4.35 billion and non-GAAP earnings of $2.10 to $2.16 per share. The Company is raising the core revenue growth guidance of 4.0% to 4.5% provided in November by 25 basis points, or $11 million. The new core revenue growth guidance is therefore 4.25% to 4.75%. However, Agilent noted that the strengthening of the US dollar since its November guidance is expected to have a negative impact of about $36 million on full-year reported revenues. The Company's FY17 guidance of $825 million operating cash flow, $200 million CapEx, and buyback of $430 million for the year remained unchanged. For Q2 FY17, Agilent expects revenue in the range of $1.04 billion to $1.06 billion, where the midpoint corresponds to a core revenue growth of 3.5%. The Company's non-GAAP earnings are expected to be in the range of $0.47 to $0.49 per share for Q2 FY17, a 9% y-o-y increase at midpoint. At the closing bell, on Friday, February 17, 2017, Agilent Technologies' stock climbed 1.55%, ending the trading session at $51.63. A total volume of 2.20 million shares were traded at the end of the day, which was higher than the 3-month average volume of 2.05 million shares. In the last three months and previous twelve months, shares of the Company have advanced 12.13% and 39.41%, respectively. Moreover, the stock surged 13.32% since the start of the year. The Company's shares are trading at a PE ratio of 33.22 and have a dividend yield of 1.03%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 21, 2017 / Active Wall St. announces its post-earnings coverage on Agilent Technologies, Inc. (NYSE: A). The Company announced its first quarter fiscal 2017 financial results on February 14, 2017. The scientific instrument maker reported eighth consecutive quarter of improving profitability and also raised its core revenue guidance for the year. Register with us now for your free membership at: One of Agilent Technologies' competitors within the Medical Laboratories & Research space, Quintiles IMS Holdings, Inc. (NYSE: Q), reported its Q4 and full-year 2016 financial results and issued its 2017 guidance on Tuesday, February 14, 2017. AWS will be initiating a research report on Quintiles IMS Holdings in the coming days. Today, AWS is promoting its earnings coverage on A; touching on Q. Get our free coverage by signing up to: For the period ended January 31, 2017, Agilent reported revenue of $1.07 billion, up 3.8% or 4.8% on core basis compared to revenue of $1.03 billion in Q1 FY16. The Company's revenue numbers surpassed analysts' consensus of $1.04 billion. For Q1 FY17, Agilent reported GAAP net income of $168 million, or $0.52 per share, compared to GAAP net income of $121 million, or $0.36 per share, for Q1 FY16. During the reported quarter, Agilent had intangible amortization of $31 million, acquisition and integration costs of $16 million, transformation costs of $2 million, and $2 million of other costs. Excluding these items, a pension settlement gain of $32 million and a tax benefit of $15 million, Agilent reported Q1 FY17 non-GAAP net income of $172 million, or $0.53 per share, exceeding Wall Street's expectations for earnings of $0.49 per share. Mike McMullen, Agilent's President and CEO stated in regards to the Company's results: "Our strong revenue results were driven by a return to growth in our Chemical & Energy business and higher-than-expected China growth. Overall, we are confident in the Company's prospects, and we are raising our full-year core revenue growth expectations." For Q1 FY17, Agilent reported adjusted operating margin of 21.2%, up 100 basis points from Q1 FY16, and operating cash flow of $116 million, $5 million higher than Q1 of last year. During Q1 FY17, Agilent paid $42 million in dividends and repurchased 2.5 million shares for $111 million in the reported quarter. The Company closed on $70 million Multiplicom acquisition in January 2017. For Q1 FY17, the Company's revenue of $540 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 3% on y-o-y basis, or 4% on a core basis, with strength in Pharma, food, chemical, and energy. LSAG's operating margin for the reported quarter was 23.4%. The Company's Agilent CrossLab Group (ACG) revenue grew 6% y-o-y, or 7% on a core basis, to $363 million. Both services and consumables experienced healthy growth across all geographies. ACG's operating margin for the reported quarter was 20.3%. During Q1 FY17, Agilent's Diagnostics and Genomics Group (DGG) generated revenue of $164 million, up 4% on y-o-y and core basis, led by strength in Dako-branded products and nucleic acid solutions. The segment's operating margin totaled 14.3% for the reported quarter. On a geographical basis, Agilent reported delivering low double digit growth in Q1FY17 in China, above the Company's expectations. The Americas reported growth in mid-single digits, with strength in the United States. Europe and Japan remained flat. For FY17, Agilent expects revenue of $4.33 billion to $4.35 billion and non-GAAP earnings of $2.10 to $2.16 per share. The Company is raising the core revenue growth guidance of 4.0% to 4.5% provided in November by 25 basis points, or $11 million. The new core revenue growth guidance is therefore 4.25% to 4.75%. However, Agilent noted that the strengthening of the US dollar since its November guidance is expected to have a negative impact of about $36 million on full-year reported revenues. The Company's FY17 guidance of $825 million operating cash flow, $200 million CapEx, and buyback of $430 million for the year remained unchanged. For Q2 FY17, Agilent expects revenue in the range of $1.04 billion to $1.06 billion, where the midpoint corresponds to a core revenue growth of 3.5%. The Company's non-GAAP earnings are expected to be in the range of $0.47 to $0.49 per share for Q2 FY17, a 9% y-o-y increase at midpoint. At the closing bell, on Friday, February 17, 2017, Agilent Technologies' stock climbed 1.55%, ending the trading session at $51.63. A total volume of 2.20 million shares were traded at the end of the day, which was higher than the 3-month average volume of 2.05 million shares. In the last three months and previous twelve months, shares of the Company have advanced 12.13% and 39.41%, respectively. Moreover, the stock surged 13.32% since the start of the year. The Company's shares are trading at a PE ratio of 33.22 and have a dividend yield of 1.03%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Loading Genomics Group collaborators
Loading Genomics Group collaborators